The STOP Nitazenes Act would amend the Controlled Substances Act to permanently place 2-benzylbenzimidazole opioids, commonly called nitazenes, into Schedule I. That means any material, compound, mixture, or preparation containing a nitazene—or its salts, isomers, and salts of isomers—would be treated as a Schedule I controlled substance unless specifically exempted or listed elsewhere. The bill also directs the Attorney General to issue implementing rules within 1 year, with the option to use an interim final rule.
What This Bill Does
- Adds nitazenes to Schedule I of the Controlled Substances Act in Section 202(c).
- Covers any material containing any quantity of a 2-benzylbenzimidazole opioid, including salts and isomers.
- Names specific substances such as etonitazene, clonitazene, metonitazene, and isotonitazene.
- Treats substances already temporarily scheduled under section 201(h) as permanently scheduled on enactment.
- Requires the Attorney General to issue implementing rules within 1 year, with the option of an interim final rule.
Who This Bill Affects
For the general public, this bill would mainly affect people involved in the illicit opioid supply, drug enforcement, public health response, and lab or research work that handles controlled-substance chemistry. If you are not using, producing, trafficking, or studying nitazenes, the direct personal impact is limited, but the bill could still affect community overdose risk by making federal control more permanent and specific. It also creates a stricter legal environment for anyone who works with the listed substances or closely related compounds.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Law enforcement and drug interdiction officials They would likely support the bill because it gives them a permanent federal Schedule I basis to investigate, seize, and prosecute nitazenes instead of relying on temporary scheduling. A fixed schedule can make enforcement more predictable when dealing with rapidly changing synthetic opioids.
- Public health and overdose prevention advocates They may argue the bill helps respond to a dangerous opioid class that can contribute to overdose deaths and is hard to control once it enters the illicit market. A permanent listing could help reduce availability and strengthen warnings for the public and first responders.
- Forensic laboratories and controlled-substance regulators Clear statutory language and an Attorney General-published list of substances can improve consistency in identification and enforcement. That can make it easier to classify seized drugs and align federal treatment of closely related analogues.
- Scientific researchers and medical laboratories They may worry that Schedule I controls make it harder to study nitazenes and related compounds, even for legitimate toxicology, forensic, or pharmacology work. More restrictive scheduling can mean more compliance burdens and delays for lab handling.
- Harm reduction and addiction treatment providers They may support the goal of limiting dangerous opioids but question whether scheduling alone reduces harm if users simply shift to other synthetic opioids. Some may argue resources should also go to testing, treatment, and overdose reversal efforts.
- Companies handling chemical intermediates or related compounds Businesses that work with closely related chemicals may fear broader compliance costs and uncertainty if their products fall within the bill’s definition or are later added to the Attorney General’s list. That can create legal risk even for firms not targeting illicit drug markets.
Key Implications
-
““permanently schedule 2-benzylbenzimidazole opioids ... as Schedule 1 controlled substances””
This means nitazenes would no longer depend on temporary emergency scheduling and would remain under the strictest federal drug controls unless Congress changes the law again.
-
““any material, compound, mixture, or preparation that contains ... any quantity””
Even trace amounts are covered, so the law would apply broadly to mixtures or products containing these substances, not just pure drug samples.
-
““The Attorney General may ... publish ... a list of substances””
Federal enforcement could be guided by an official list of covered compounds, which may help agencies and laboratories identify substances but also centralizes a lot of classification power in DOJ.
-
““shall, not later than 1 year after the date of enactment ... issue rules””
The bill requires implementing regulations within a year, so agencies would need to move quickly to translate the statutory change into practical enforcement rules.
-
““give interested persons the opportunity to comment and to request a hearing””
An interim final rule could take effect quickly, but manufacturers, researchers, and other affected parties would still have a formal chance to respond before a final rule is issued.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- HR 7970
- Congress
- 119th Congress
- Official title
- STOP Nitazenes Act
- Policy area
- Criminal Justice
- Latest action
- Forwarded by Subcommittee to Full Committee by Voice Vote. (June 25, 2026)
- Last updated
- June 27, 2026
Latest Status
June 25, 2026
Forwarded by Subcommittee to Full Committee by Voice Vote.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.